insights_auto
Per què DRUG ha pujat 2,08%?
Aprofundeix méschevron_right
DRUG:CNSX
Bright Minds Biosciences Inc
74,55 CAD
arrow_upward
+2,08%(+1,52) 1d
19 d’oct., 16:00:00 GMT-4 · CAD
search
Tots els símbols
| Símbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadístiques principals per a DRUG...
Obre
73,12 CAD
Alt
74,55 CAD
Baix
73,12 CAD
Capitalització borsària
735,37 M
Volum mitjà
871,00
Volum
330,00
Alt 52 setmanes
170,00 CAD
Baix 52 setmanes
68,02 CAD
BPA
-2,90 CAD
Nombre d'empleats
26
Obre
73,12 CAD
Alt
74,55 CAD
Baix
73,12 CAD
Capitalització borsària
735,37 M
Volum mitjà
871,00
Volum
330,00
Alt 52 setmanes
170,00 CAD
Baix 52 setmanes
68,02 CAD
BPA
-2,90 CAD
Nombre d'empleats
26
Notícies
De fonts web i partners de notícies
Kalkine Media
·
fa 17 minuts
Can AI-Driven Dash Search Keep Dropbox (NASDAQ:DBX) in Focus?
The Guardian
·
fa 44 minuts
Is this the beginning of the end of the AI stock market boom?
upi
·
fa 12 hores
New York Stock Exchange extends trading hours
Perfil
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
Sobre Bright Minds Biosciences Inc